SHMT2 and glioma: These findings are similar to previous studies which have demonstrated an upregulation of SHMT2 in several cancers such as lymphoma, glioma, cholangiocarcinoma, breast cancer, gastric cancer, lung adenocarcinoma and colorectal cancer [6, 7, 14, 16].